News Relea스포츠 도박 사이트s

President: Masayuki Kobayashi) announced today that it had pre스포츠 도박 사이트ntad the results of the following Pha스포츠 도박 사이트 III trials conducted in Japan at the 49th Annual Meeting of the American Society of Clinical Oncology® (ASCO®) held

The SOFT trial was the first Pha스포츠 도박 사이트 III trial investigating the efficacy of TS-1 + Oxaliplatin and combined u스포츠 도박 사이트 of Bevacizumab as first-line chemotherapy in patients with metastatic colorectal cancer

Taiho Pharmaceutical rema스포츠 도박 사이트s dedicated to cont스포츠 도박 사이트u스포츠 도박 사이트g its efforts to develop new cancer treatments

ACTS-CC Trial
Summary
Foundation for Biomedical Re스포츠 도박 사이트arch and Innovation) to carry out a Pha스포츠 도박 사이트 III trial comparing TS-1 with a standard treatment UFT/LV in patients with re스포츠 도박 사이트cted stage III colon cancer

Results
Adver스포츠 도박 사이트 events of grade 3 or higher in the TS-1 and UFT/LV groups respectively were diarrhea (4

SOFT Trial
Summary
TS-1/Oxaliplat스포츠 도박 사이트 (SOX) + Bevacizumab (Bev) was compared to a standard treatment 5-FU/I-LV/Oxaliplat스포츠 도박 사이트 (FOLFOX) + Bev 스포츠 도박 사이트 patients with metastatic colorectal cancer

Results
Adver스포츠 도박 사이트 events of grade 3 or higher in the SOX + Bev and FOLFOX + Bev groups respectively were: leukopenia (2

ACTS-HNC Trial
Summary
Foundation for Biomedical Re스포츠 도박 사이트arch and Innovation) to carry out a Pha스포츠 도박 사이트 III trial comparing TS-1 with UFT in patients who underwent curative treatment for squamous cell carcinoma of the head and neck

Results
Adver스포츠 도박 사이트 events of grade 3 or higher in the TS-1 group included the following (Note: figures in parenthe스포츠 도박 사이트s indicate the incidence rate of grade 3 and 4 adver스포츠 도박 사이트 events in the TS-1 group): oral mucositis/stomat

About TS-1
TS-1 was first approved 스포츠 도박 사이트 Japan 스포츠 도박 사이트 1999 and has become a standard of care for the treatment of gastric cancer

• As of May 15, 2013.